Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.654,80
0,26%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Zai Lab Ltd (ZLAB) Zai Lab Ltd (ZLAB) Notizie

ZLAB

Zai Lab (ZLAB)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ZLAB
DataOraFonteTitoloSimboloCompagnia
22/05/202413:30Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque PsoriasisNASDAQ:ZLABZai Lab Ltd
20/05/202406:21Business WireZai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Baumannii-Calcoaceticus Complex in ChinaNASDAQ:ZLABZai Lab Ltd
16/05/202422:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZLABZai Lab Ltd
16/05/202413:30Business WireZai Lab Announces Participation in May and June Investor ConferencesNASDAQ:ZLABZai Lab Ltd
14/05/202419:22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ZLABZai Lab Ltd
14/05/202413:30Business WireZai Lab Announces Acceptance of Supplemental Biologics License Application with Priority Review for Efgartigimod Alfa Injection (Subcutaneous Injection) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in ChinaNASDAQ:ZLABZai Lab Ltd
13/05/202402:20Business WireZai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China’s NMPANASDAQ:ZLABZai Lab Ltd
08/05/202422:14Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZLABZai Lab Ltd
08/05/202422:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZLABZai Lab Ltd
08/05/202422:05Business WireZai Lab Announces First Quarter 2024 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
15/04/202413:30Business WireZai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024NASDAQ:ZLABZai Lab Ltd
11/04/202413:30Business WireZai Lab Statement on Executive Management Team’s Agreement on Share ActivitiesNASDAQ:ZLABZai Lab Ltd
02/04/202413:30Business WireZai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology ProgramsNASDAQ:ZLABZai Lab Ltd
01/04/202413:30Business WireZai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...NASDAQ:ZLABZai Lab Ltd
27/03/202414:29Business WireZai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung CancerNASDAQ:ZLABZai Lab Ltd
14/03/202400:05Business WireZai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid TumorsNASDAQ:ZLABZai Lab Ltd
06/03/202422:01Business WireZai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)NASDAQ:ZLABZai Lab Ltd
06/03/202413:30Business WireZai Lab Announces Participation in March Investor ConferenceNASDAQ:ZLABZai Lab Ltd
27/02/202422:20Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ZLABZai Lab Ltd
27/02/202422:05Business WireZai Lab Announces Full-Year 2023 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
25/01/202422:15Business WireZai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024NASDAQ:ZLABZai Lab Ltd
10/01/202423:12Business WireZai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLCNASDAQ:ZLABZai Lab Ltd
22/12/202322:29Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:ZLABZai Lab Ltd
19/12/202313:30Business WireZai Lab Announces Participation in January Investor ConferenceNASDAQ:ZLABZai Lab Ltd
13/12/202314:53GlobeNewswire Inc.Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug ListNASDAQ:ZLABZai Lab Ltd
13/12/202305:10Business WireZai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug ListNASDAQ:ZLABZai Lab Ltd
07/11/202322:05GlobeNewswire Inc.Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate UpdatesNASDAQ:ZLABZai Lab Ltd
26/10/202313:30GlobeNewswire Inc.Zai Lab Announces Participation in November Investor ConferencesNASDAQ:ZLABZai Lab Ltd
18/10/202313:30GlobeNewswire Inc.Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023NASDAQ:ZLABZai Lab Ltd
18/09/202313:30GlobeNewswire Inc.Zai Lab Obtains Breakthrough Therapy Designation for Efgartigimod Alfa Injection (Subcutaneous Injection) in Patients with Chronic Inflammatory Demyelinating Polyneuropathy in ChinaNASDAQ:ZLABZai Lab Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ZLAB

La tua Cronologia

USOTC
PPAAY
PT Perusahaan Gas Negara... (PK)
LSE
ATST
Alliance
TG
NEM
Nemetschek
COIN
SOLBRL
Solana
BIT
P20SG0
NLBNPIT20SG0 20241220 30
BIT
P20DG2
NLBNPIT20DG2 20991231 12...
BIT
P1ZRO3
NLBNPIT1ZRO3 20351221 10...
LSE
ZP57
Euro.bk. 26
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network